IGFBP7 and gastric cancer: For cell proliferation and migration, cell cycle analysis and Transwell assays indicated that the percentage of GC cells in the S phase and the percentage of migrating cells were significantly increased in the group cocultured with IGFBP7‐overexpressing cells, while ruxolitinib treatment significantly reversed these increases (Figure 7E–G).